Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications-pMMR vs dMMR Disease, Molecular Considerations in the Recurrent and First Line Setting

pMMR vs dMMR Disease, Molecular Considerations in the Recurrent and First Line Setting

Video Transcription

Video Summary

Dr. Brian Slomovitz moderates a symposium on personalized management of advanced or recurrent endometrial cancers, highlighting the importance of molecular subclassifications, specifically PMMR and DMMR. Dr. John Chan reflects on the rising incidence of uterine cancer, now the most common and lethal gynecologic cancer in the U.S., and discusses disparities affecting African American and Hispanic women. The presentation delves into the role of molecular biomarkers in treatment strategies, exploring the application of immunotherapies and targeted therapies. Trials like RUBY, GY018, and DOE are reevaluated for their treatment guidelines. Dr. Chan emphasizes the need for personalized strategies based on tumor markers and patient history, suggesting the potential for repurposing drugs in recurrent settings. Despite trial variations, the challenge remains in determining optimal treatments, with current options including a combination of immune checkpoint inhibitors and tyrosine kinase inhibitors. Audience engagement highlights a pressing need for further research, particularly on the P53 mutation subgroup.

Asset Subtitle

John Chan (United States of America)

Keywords

endometrial cancer

molecular subclassifications

treatment strategies

disparities

immunotherapies

biomarkers